Keyphrases
Visual Acuity
100%
Initial Treatment
100%
Best-corrected Visual Acuity
100%
Age-related Macular Degeneration
100%
Short Intervals
100%
Myopic Choroidal Neovascularization (mCNV)
100%
Intravitreal Injection
100%
Intravitreal Bevacizumab
100%
Macular Volume
100%
Decision Maker
50%
Long Interval
50%
Realistic Scenario
50%
Additional Resources
50%
Patients Included
50%
Optical Coherence Tomography
50%
Largest Mean
50%
Visual Outcome
50%
Intravitreal Ranibizumab
50%
Outcome Costs
50%
Naïve Eyes
50%
Retinal Volume
50%
Nursing and Health Professions
Visual Acuity
100%
Bevacizumab
100%
Best Corrected Visual Acuity
66%
Age Related Macular Degeneration
66%
Intravitreal Drug Administration
66%
Subretinal Neovascularization
66%
Hospital
33%
Physician
33%
Cohort Analysis
33%
Optical Coherence Tomography
33%
Medicine and Dentistry
Visual Acuity
100%
Bevacizumab
100%
Best Corrected Visual Acuity
66%
Intravitreal Administration
66%
Age Related Macular Degeneration
66%
Choroidal Neovascularization
66%
Health Care Cost
33%
Cohort Analysis
33%
Optical Coherence Tomography
33%
Neuroscience
Bevacizumab
100%
Age-Related Macular Degeneration
66%
Choroidal Neovascularization
66%